Search
Lartesertib
go.drugbank.com/drugs/DB19045InvestigationalLartesertib is under investigation in clinical trial NCT06433219 (Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (Ddriver EOC 302)).
Synonyms: 2H-Imidazo[4,5-c]quinolin-2-one, 8-(1,3-dimethyl-1H-pyrazol-4-yl)-1-(3-fluoro-5-methoxy-4-pyridinyl)-1,3-dihydro-7-methoxy-3-methyl-, (1S)-, 8-(1,3-dimethyl-1h-pyrazol-4-yl)-1-(3-fluoro-5-methoxy-4-pyridinyl)-1,3-dihydro-7-methoxy-3-methyl-2h-imidazo(4,5-c)quinolin-2-oneTanfanercept
go.drugbank.com/drugs/DB19142InvestigationalTanfanercept is under investigation in clinical trial NCT06400589 (A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease).
Synonyms: L-methionyl-(l28>v,s52>m,h55>f,r57>p,h58>g,k121>n) tumor necrosis factor (tnf) binding protein variant 1 (tbp-1) with c-terminal extension by further 10 residues of the pro-protein, human, unglycosylated, 41-211-tumor necrosis factor receptor 1Raludotatug deruxtecan
go.drugbank.com/drugs/DB19447InvestigationalRaludotatug deruxtecan is under investigation in clinical trial NCT06660654 (A Study of Raludotatug Deruxtecan in Participants With Advanced/metastatic Solid Tumors (Rejoice-pantumor01)).
Synonyms: R-DXd, immunoglobulin G1-kappa, anti-[Homo sapiens CDH6(cadherin 6, K-cadherin (foetal kidney), cadherin 6 type 2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecinGP-100 antigen
go.drugbank.com/drugs/DB14800InvestigationalGP-100 antigen is under investigation in clinical trial NCT00006385 (Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma).
Selonsertib
go.drugbank.com/drugs/DB14916InvestigationalSelonsertib is under investigation in clinical trial NCT03053050 (Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis).
Synonyms: 5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-{6-[4-(propan-2-yl)-4H-1,2,4-triazol-3-yl]pyridin-2-yl}benzamide, 5-(4-Cyclopropyl-1H-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamideCategories: Heterocyclic Compounds, 1-RingPF-03382792
go.drugbank.com/drugs/DB12949InvestigationalPf 03382792 is under investigation in clinical trial NCT01045863 (To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers).
Patritumab deruxtecan
go.drugbank.com/drugs/DB21996InvestigationalPatritumab deruxtecan is under investigation in clinical trial NCT06596694 (Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)).
Pimivalimab
go.drugbank.com/drugs/DB16667InvestigationalPimivalimab is under investigation in clinical trial NCT04549025 (Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After
Pixatimod
go.drugbank.com/drugs/DB19166InvestigationalPixatimod is under investigation in clinical trial NCT05061017 (Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide … in MSS Metastatic Colorectal Carcinoma (Mcrc)).
IK-930
go.drugbank.com/drugs/DB18149InvestigationalIK-930 is an oral, paralog-selective TEAD inhibitor.